National Institute on Drug Abuse; Notice of Closed Meetings, 78671-78672 [2011-32424]

Download as PDF Federal Register / Vol. 76, No. 243 / Monday, December 19, 2011 / Notices Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: December 13, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. emcdonald on DSK5VPTVN1PROD with NOTICES [FR Doc. 2011–32459 Filed 12–16–11; 8:45 am] National Institute on Drug Abuse; Notice of Closed Meetings BILLING CODE 4140–01–P National Institute of Mental Health; Notice of Closed Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: National Institute of Child Health and Human Development; Special Emphasis Panel. Folic Acid Supplementation and Semen Quality Trial. Date: January 10, 2012. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, (301) 435–6680, skandasa@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) 19:31 Dec 16, 2011 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4160–01–P VerDate Mar<15>2010 Dated: December 13, 2011. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2011–32368 Filed 12–16–11; 8:45 am] Jkt 226001 78671 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel, NIMH K22 Review. Date: January 5, 2012. Time: 12 p.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852 (Telephone Conference Call). Contact Person: David M. Armstrong, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center/ Room 6138/MSC 9608, 6001 Executive Boulevard Bethesda, MD 20892–9608, (301) 443–3534, armstrda@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: December 12, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–32425 Filed 12–16–11; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Drugged Driving: Future Research Directions (5569). Date: January 11, 2012. Time: 12 p.m. to 5 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852 (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, Ph.D. Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, Bethesda, MD 20892–9550, (301) 402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Feasibility of Development of RNAi-based Therapeutics for Treatment of HIV and HVC Infections in Drug Abusing Populations (8907). Date: January 13, 2012. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852 (Telephone Conference Call). Contact Person: Minna Liang, Ph.D., Scientific Review Officer, Grants Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4226, MSC 9550, Bethesda, MD 20892–9550, (301) 435–1432, liangm@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Development of a Solid Dosage Form for Fenobam (8906). Date: January 18, 2012. Time: 11 a.m. to 5 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive E:\FR\FM\19DEN1.SGM 19DEN1 78672 Federal Register / Vol. 76, No. 243 / Monday, December 19, 2011 / Notices Boulevard Rockville, MD 20852 (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, Bethesda, MD 20892–9550, (301) 402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Smokescreen: Genetic Screening Tool for Tobacco Dependence and Treatment Approaches (7783). Date: January 19, 2012. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852, (Virtual Meeting). Contact Person: Minna Liang, Ph.D., Scientific Review Officer, Grants Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6001 Executive Blvd. Room 4226, MSC 9550, Bethesda, MD 20892–9550, (301) 435–1432, liangm@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: December 13, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–32424 Filed 12–16–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health emcdonald on DSK5VPTVN1PROD with NOTICES National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Grand Opportunity in Medications Development for Substance-Related Disorders (U01). Date: January 6, 2012. Time: 1 p.m. to 4 p.m. VerDate Mar<15>2010 19:31 Dec 16, 2011 Jkt 226001 Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892– 9550, (301) 451–3086, ruizjf@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: December 13, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–32422 Filed 12–16–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of a meeting of the Literature Selection Technical Review Committee. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended because the premature disclosure of journals as potential titles to be indexed by the National Library of Medicine and the discussions would likely to significantly frustrate implementation of recommendations. Name of Committee: Literature Selection Technical Review Committee. Date: February 23–24, 2012. Open: February 23, 2012, 9 a.m. to 11 a.m. Agenda: Administrative. Place: National Library of Medicine, Building 38, 2nd Floor, Board Room, 8600 Rockville Pike, Bethesda, MD 20894. Closed: February 23, 2012, 11 a.m. to 5 p.m. Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine. PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 Place: National Library of Medicine, Building 38, 2nd Floor, Board Room, 8600 Rockville Pike, Bethesda, MD 20894. Closed: February 24, 2012, 8:30 a.m. to 2 p.m. Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine. Place: National Library of Medicine, Building 38, 2nd Floor, Board Room, 8600 Rockville Pike, Bethesda, MD 20894. Contact Person: Sheldon Kotzin, MLS, Associate Director, Division of Library Operations, National Library of Medicine, 8600 Rockville Pike, Building 38, Room 2W06, Bethesda, MD 20892, (301) 496–6921, kotzins@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS). Dated: December 13, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–32426 Filed 12–16–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of meetings of the Board of Regents of the National Library of Medicine. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections E:\FR\FM\19DEN1.SGM 19DEN1

Agencies

[Federal Register Volume 76, Number 243 (Monday, December 19, 2011)]
[Notices]
[Pages 78671-78672]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-32424]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Drugged Driving: Future Research Directions (5569).
    Date: January 11, 2012.
    Time: 12 p.m. to 5 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D. Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, (301) 402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Feasibility of Development of RNAi-based 
Therapeutics for Treatment of HIV and HVC Infections in Drug Abusing 
Populations (8907).
    Date: January 13, 2012.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Minna Liang, Ph.D., Scientific Review Officer, 
Grants Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4226, 
MSC 9550, Bethesda, MD 20892-9550, (301) 435-1432, 
liangm@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of a Solid Dosage Form for Fenobam 
(8906).
    Date: January 18, 2012.
    Time: 11 a.m. to 5 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive

[[Page 78672]]

Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, (301) 402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Smokescreen: Genetic Screening Tool for Tobacco 
Dependence and Treatment Approaches (7783).
    Date: January 19, 2012.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Minna Liang, Ph.D., Scientific Review Officer, 
Grants Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse, NIH, 6001 Executive Blvd. Room 4226, MSC 
9550, Bethesda, MD 20892-9550, (301) 435-1432, liangm@nida.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: December 13, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-32424 Filed 12-16-11; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.